Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Novo Nordisk CEO Says "Over The Next Quarter Seeing A Steady Flow Of Trial Data For Semaglutide"; "When We Now Launch In New Countries, We Want To Do It In A Way Where We Set Aside A Defined Capacity" For Obesity Drug; "Pleased With" The Catalent Acquisition That We're Now Working On And We Expect To Close In This Year

Author: Benzinga Newsdesk | May 21, 2024 10:54am

- Reuters

Posted In: NVO